Copertina

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ankit Kumar, Amol N. Patil, Jyoti Grewal, J. Kumaravel, Muhammad Aaqib Shamim, Aravind Sekar, Anuraag Jena, Anupam K. Singh, Ashish Kakkar, Usha Dutta, Vishal Sharma
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
di: Amol N. Patil, et al.
Pubblicazione: (2026)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
di: Ganesh Bhat, et al.
Pubblicazione: (2026)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
di: Hariti Saluja, et al.
Pubblicazione: (2026)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
di: Rónán O'Connor, et al.
Pubblicazione: (2026)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
di: Ankit Kumar, et al.
Pubblicazione: (2026)

Letter: Steroid Tapering—Is Shorter Duration Better?
di: Juntao Lu, et al.
Pubblicazione: (2026)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
di: Priyadarshini Zula, et al.
Pubblicazione: (2026)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial
di: Rie Louise Møller Nordestgaard, et al.
Pubblicazione: (2025)

Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease
di: Abhirup Chatterjee, et al.
Pubblicazione: (2024)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
di: Anupam Kumar Singh, et al.
Pubblicazione: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
di: Pardhu Bharath Neelam, et al.
Pubblicazione: (2025)

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
di: Parambir S. Dulai, et al.
Pubblicazione: (2024)

Editorial: Striving for Equitable Care in Ulcerative Colitis
di: Edward L. Barnes
Pubblicazione: (2025)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
di: Brian C. Weiner
Pubblicazione: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
di: Richard Pollok
Pubblicazione: (2025)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
di: Silvio Danese, et al.
Pubblicazione: (2025)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
di: Matthew K. W. Chu, et al.
Pubblicazione: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Antoine Meyer, et al.
Pubblicazione: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimization
di: Pranab M. Barman
Pubblicazione: (2026)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
di: Veeral Ajmera, et al.
Pubblicazione: (2026)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
di: Anish J. Kuriakose Kuzhiyanjal, et al.
Pubblicazione: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
di: Arshdeep Singh, et al.
Pubblicazione: (2025)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
di: Shintaro Akiyama
Pubblicazione: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
di: J. Couch, et al.
Pubblicazione: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
di: Johan D. Söderholm
Pubblicazione: (2025)

Editorial: Steroid‐Induced Diabetes in Autoimmune Hepatitis—A Call for Treatment Optimisation. Authors' Reply
di: Sarah Flatley
Pubblicazione: (2026)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
di: Sarah Melton, et al.
Pubblicazione: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
di: Mark A. Ainsworth, et al.
Pubblicazione: (2025)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
di: Aakash Desai, et al.
Pubblicazione: (2025)

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
di: Tom van Gils, et al.
Pubblicazione: (2024)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
di: Laurie‐Rose Dubé, et al.
Pubblicazione: (2026)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
di: Matheus Souza, et al.
Pubblicazione: (2025)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
di: Mathilde Osty, et al.
Pubblicazione: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
di: María Chaparro, et al.
Pubblicazione: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
di: Shinichiro Shinzaki, et al.
Pubblicazione: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
di: J. Couch, et al.
Pubblicazione: (2025)